Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Asparaginase Erwinia chrysanthemi
Synonyms
Therapy Description

Erwinaze (asparaginase Erwinia chrysanthemi) is an bacterial derived enzyme that converts L-asparagine to L-aspartate and ammonia, which decreases L-asparagine levels, potentially leading to reduced leukemic cell growth (PMID: 25098829, PMID: 26698391). Erwinaze (asparaginase Erwinia chrysanthemi) is FDA-approved for use in a chemotherapeutic regimen for acute lymphoblastic leukemia (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Asparaginase Erwinia chrysanthemi Erwinaze Crisantaspase Erwinaze (asparaginase Erwinia chrysanthemi) is an bacterial derived enzyme that converts L-asparagine to L-aspartate and ammonia, which decreases L-asparagine levels, potentially leading to reduced leukemic cell growth (PMID: 25098829, PMID: 26698391). Erwinaze (asparaginase Erwinia chrysanthemi) is FDA-approved for use in a chemotherapeutic regimen for acute lymphoblastic leukemia (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02521493 Phase III Etoposide Thioguanine Cytarabine Asparaginase Erwinia chrysanthemi mitoxantrone hydrochloride Daunorubicin Asparaginase Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Active, not recruiting USA | CAN 4


Additional content available in CKB BOOST